PDGFRB and cholangiocarcinoma: The result demonstrated that all PDGFR inhibitors exhibited a dose-dependent decrease in CCA cells (Figure 3A–C), with half maximal inhibitory concentration (IC50) values ranging from 4.81 to 13.97 μM (Figure 3D).